About Event
Discovering the Future of Cell & Gene Therapy
This once-a-year meeting uniting C-level executives, VPs, and Directors in Discovery, Pre-Clinical, and Translational fields developing in vivo cell engineering and gene editing pipelines to showcase various approaches in animal modeling and delivery, clarify regulatory ambiguity and create actionable solutions to advance pipelines to the next stage.
Agenda Highlights
Optimizing target specificity to deliver payloads effectively with limited off-site toxicities with Argobio Studio, Editas Medicine, Mammoth Biosciences, and Primera Therapeutics
Delving into the relationship between efficacy and toxicity to strike a balance with Mustang Bio and Vyriad Pharma
Navigating different animal models such as humanized mice and non-human primate models to find the most suitable model for your studies with Sanofi and University of Massachusetts
Assessing the different modes of delivery by showcasing both viral and non-viral mechanisms with Abintus Bio, Alaya.bio, Capstan Therapeutics, NanoCell Therapeutics, and Sanofi
Understanding in vivo cell engineering beyond oncology into autoimmune indications to expand the therapeutic potential of treatments with Orna Therapeutics
Planning to scale from current pre-clinical stages into the clinic to gain insights from the closest companies with Capstan Therapeutics
 |
Optimizing target specificity to deliver payloads effectively with limited off-site toxicities with Argobio Studio, Editas Medicine, Mammoth Biosciences, and Primera Therapeutics |
|
Delving into the relationship between efficacy and toxicity to strike a balance with Mustang Bio and Vyriad Pharma |
|
Navigating different animal models such as humanized mice and non-human primate models to find the most suitable model for your studies with Sanofi and University of Massachusetts |
|
Assessing the different modes of delivery by showcasing both viral and non-viral mechanisms with Abintus Bio, Alaya.bio, Capstan Therapeutics, NanoCell Therapeutics, and Sanofi |
|
Understanding in vivo cell engineering beyond oncology into autoimmune indications to expand the therapeutic potential of treatments with Orna Therapeutics |
|
Planning to scale from current pre-clinical stages into the clinic to gain insights from the closest companies with Capstan Therapeutics |
Download the Full Agenda for More Information on:
-
-
-
- 15+ In Vivo Expert Speakers
- 2 Interactive Deep-Dive Workshops
- 8+ Hours of Industry Networking
- & Much More!
-
-
